ES2176468T3 - Uso de acido hialuronico y un nsaid para la fabricacion de un medicamento para el tratamiento de enfermedades de las mucosas. - Google Patents

Uso de acido hialuronico y un nsaid para la fabricacion de un medicamento para el tratamiento de enfermedades de las mucosas.

Info

Publication number
ES2176468T3
ES2176468T3 ES96922722T ES96922722T ES2176468T3 ES 2176468 T3 ES2176468 T3 ES 2176468T3 ES 96922722 T ES96922722 T ES 96922722T ES 96922722 T ES96922722 T ES 96922722T ES 2176468 T3 ES2176468 T3 ES 2176468T3
Authority
ES
Spain
Prior art keywords
nsaid
diseases
mucose
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96922722T
Other languages
English (en)
Inventor
Samuel Simon Asculai
Rudolf Edgar Falk
Alan L Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AG filed Critical Jagotec AG
Application granted granted Critical
Publication of ES2176468T3 publication Critical patent/ES2176468T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE UNA CANTIDAD EFICAZ DE UNA COMPOSICION FORMADA POR UN AINE Y UNA FORMA DE ACIDO HIALURONICO SELECCIONADA A PARTIR DE ACIDO HIALURONICO, SUS SALES FARMACOLOGICAMENTE ACEPTABLES, FRAGMENTOS Y/O SUBUNIDADES PARA EL ALIVIO DE LOS TRAUMATISMOS, ENFERMEDADES Y/O DOLOR DE LAS MEMBRANAS.
ES96922722T 1995-07-18 1996-07-18 Uso de acido hialuronico y un nsaid para la fabricacion de un medicamento para el tratamiento de enfermedades de las mucosas. Expired - Lifetime ES2176468T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002154103A CA2154103C (en) 1995-07-18 1995-07-18 Treatment of mucous membrane disease, trauma or condition and for the relief of pain

Publications (1)

Publication Number Publication Date
ES2176468T3 true ES2176468T3 (es) 2002-12-01

Family

ID=4156246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96922722T Expired - Lifetime ES2176468T3 (es) 1995-07-18 1996-07-18 Uso de acido hialuronico y un nsaid para la fabricacion de un medicamento para el tratamiento de enfermedades de las mucosas.

Country Status (10)

Country Link
US (1) US6159955A (es)
EP (1) EP0839052B1 (es)
JP (1) JP4194653B2 (es)
AT (1) ATE217197T1 (es)
AU (1) AU719257B2 (es)
CA (1) CA2154103C (es)
DE (1) DE69621132T2 (es)
ES (1) ES2176468T3 (es)
NZ (1) NZ312073A (es)
WO (1) WO1997003699A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US5981499A (en) * 1998-02-20 1999-11-09 Atlantic Biomed Corporation Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
JP4685242B2 (ja) * 1998-10-22 2011-05-18 バイオニケ・テオランタ ヒアルロン酸を用いた放射線膀胱炎の予防、軽減、および治療法
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
US6607745B2 (en) 2001-05-18 2003-08-19 Harry Leneau Ingestion of hyaluronic acid for improved joint function and health
ITBO20010361A1 (it) * 2001-06-07 2002-12-07 Farma Derma S R L Uso di acido ialuronico per la produzione di un preparato ad uso vaginale, in particolare per la cura degli stati atrofici e distrofici cerv
JP2005526114A (ja) * 2002-05-06 2005-09-02 コッラジェネックス ファーマシューチカルス インコーポレイテッド 粘膜炎及び真菌感染症の同時治療方法
TR200201556A2 (tr) * 2002-06-12 2004-01-21 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve nonsteroidal antienflamatuar içeren farmasötik bileşim
US8129359B2 (en) * 2004-06-04 2012-03-06 Ethicon, Inc. Composition and method for treating post-surgical pain
US8377906B2 (en) * 2004-06-04 2013-02-19 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
CN101522164B (zh) 2006-09-13 2014-03-26 提升肤质产品公司 用于治疗皮肤的化妆品组合物及其方法
WO2008145149A1 (en) * 2007-05-28 2008-12-04 Vincenzo Massimo Lombardo Antiphlogistic and analgesic composition for topical use in a region of an animal locomotive system
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
IT1401351B1 (it) * 2010-07-28 2013-07-18 Galsor S R L Composizione farmaceutica a base di una o più frazioni di acido ialuronico o suoi sali in associazione con un inibitore della ialuronidasi e suoi usi in campo medico
ES2667854T3 (es) 2011-07-07 2018-05-14 Holy Stone Healthcare Co., Ltd. Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación
ES2665254T3 (es) 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
JPWO2016153015A1 (ja) * 2015-03-25 2018-05-10 株式会社ファルマクリエ神戸 高分子薬効成分を含有した口腔内施用物および口腔内への高分子薬効成分の投与方法
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) * 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11633352B2 (en) 2018-01-09 2023-04-25 E2Bio Life Science, LLC Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia
WO2020117546A1 (en) * 2018-12-03 2020-06-11 Samuel Asculai Pharmaceutical formulations and compositions suitable to treat mucositis
WO2020160344A1 (en) * 2019-02-01 2020-08-06 Ehrenpreis Eli D Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
EP0138572B1 (en) * 1983-10-11 1990-07-25 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
JPS63101332A (ja) * 1986-10-17 1988-05-06 Sato Seiyaku Kk 経口投与用徐放性製剤
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP2951681B2 (ja) * 1990-02-23 1999-09-20 株式会社資生堂 経粘膜投与用薬剤組成物
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US6017900A (en) * 1991-07-03 2000-01-25 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and nsaids
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
JPH0717870A (ja) * 1993-06-29 1995-01-20 Toshiko Yamamoto トローチ剤

Also Published As

Publication number Publication date
EP0839052B1 (en) 2002-05-08
US6159955A (en) 2000-12-12
ATE217197T1 (de) 2002-05-15
EP0839052A1 (en) 1998-05-06
CA2154103C (en) 1998-02-24
AU719257B2 (en) 2000-05-04
WO1997003699A1 (en) 1997-02-06
NZ312073A (en) 2000-02-28
AU6351996A (en) 1997-02-18
JP4194653B2 (ja) 2008-12-10
CA2154103A1 (en) 1997-01-19
JPH11514967A (ja) 1999-12-21
DE69621132D1 (de) 2002-06-13
DE69621132T2 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
ES2176468T3 (es) Uso de acido hialuronico y un nsaid para la fabricacion de un medicamento para el tratamiento de enfermedades de las mucosas.
FI973868L (fi) D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyperparatyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa
ES2152485T3 (es) Procedimiento para preparar comprimidos que contienen amoxicilina y clavulanato recubiertos de una pelicula polimerica acuosa.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
NO20053106L (no) Oral, analgesisk doseringsform med forlenget frigivelse.
MX9707453A (es) Derivados de quinazolina.
ES2191682T3 (es) Nueva formulacion farmaceutica.
ATE308341T1 (de) Pharmazeutische formulierungen
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2033682T3 (es) Procedimiento para preparar una composicion farmaceutica que contiene acido 2-(2-fluoro-4-bifenilil)propionico o una de sus sales.
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
MX171542B (es) Composiciones farmaceuticas que contienen deoxirribonucleosidos para cicatrizacion de heridas
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
AR025030A1 (es) Utilizacion de flupirtina para aliviar los dolores en las artropatias degenerativas en perros y gatos para la preparacion de un medicamento para eltratamiento de dichas afecciones
MX9305887A (es) Uso de acido hialuronico y formas para evitar restenosis arterial.
ES2150547T3 (es) Uso de dimeticona para la fabricacion de un medicamento para el tratamiento de aftas y estomatitis.
ES2151922T3 (es) Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
HN1998000186A (es) Forma termodinamicamente estable del acido (r)-3-(((4-fluorofenil) sulfonil amino)-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban).